[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 26, 2001

Underreporting of Hemorrhagic Stroke Associated With Phenylpropanolamine

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(24):3081. doi:10.1001/jama.286.24.3075

To the Editor: Although passive surveillance systems for adverse drug event reporting are often used to detect rare, serious adverse reactions for marketed drugs, they are limited by underreporting. The extent of underreporting is unknown and may be influenced by the severity of the event, the specialty of the reporter, how long the drug has been on the market, whether the event is labeled, and whether the drug is prescription or nonprescription.1 We attempted to assess the degree of underreporting of hemorrhagic stroke associated with phenylpropanolamine, a nonprescription drug.

First Page Preview View Large
First page PDF preview
First page PDF preview
×